Accelerate Diagnostics (NASDAQ:AXDX) Earns Hold Rating from Analysts at StockNews.com

Posted by Cynthia Vaughn on Mar 20th, 2025

StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Free Report) in a research note published on Monday. The firm issued a hold rating on the medical research company’s stock.

Separately, BTIG Research upgraded shares of Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th.

Check Out Our Latest Stock Report on AXDX

Accelerate Diagnostics Trading Down 1.3 %

Shares of NASDAQ AXDX opened at $1.12 on Monday. The company has a market capitalization of $27.92 million, a price-to-earnings ratio of -0.39 and a beta of 0.55. Accelerate Diagnostics has a twelve month low of $0.73 and a twelve month high of $2.09. The business has a 50 day simple moving average of $1.17 and a 200-day simple moving average of $1.46.

Institutional Trading of Accelerate Diagnostics

Several hedge funds have recently made changes to their positions in AXDX. Jane Street Group LLC bought a new position in Accelerate Diagnostics during the 4th quarter worth $27,000. Y Intercept Hong Kong Ltd bought a new position in shares of Accelerate Diagnostics during the third quarter worth about $34,000. Renaissance Technologies LLC increased its holdings in shares of Accelerate Diagnostics by 160.6% in the 4th quarter. Renaissance Technologies LLC now owns 107,062 shares of the medical research company’s stock worth $128,000 after acquiring an additional 65,984 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of Accelerate Diagnostics by 6.9% in the 4th quarter. Geode Capital Management LLC now owns 135,732 shares of the medical research company’s stock worth $163,000 after acquiring an additional 8,777 shares during the period. Institutional investors own 17.14% of the company’s stock.

About Accelerate Diagnostics

(Get Free Report)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.